Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.36 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.36 |
| ▸ | PARL | Q9H300 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874918 | 0.84 | CCNE1 (0.38) | CCNE1CDK2GSK3BMGLLALDH1A1 | |
| SCHEMBL18911357 | 0.80 | FKBP1A (0.35) | CCNE1CDK2GSK3BALDH1A1SLC16A3 | |
| SCHEMBL10617309 | 0.78 | MEN1 (0.48) | CCNE1CDK2GSK3BALDH1A1KMT2A | |
| SCHEMBL13348467 | 0.77 | MAPT (0.33) | — | |
| SCHEMBL11563416 | 0.77 | MEN1 (0.50) | CCNE1CDK2GSK3BALDH1A1KMT2A | |
| SCHEMBL11320576 | 0.77 | MEN1 (0.50) | CCNE1CDK2GSK3BALDH1A1KMT2A | |
| SCHEMBL9712261 | 0.77 | ALDH1A1 (0.41) | CCNE1CDK2GSK3BALDH1A1MAPK1 | |
| SCHEMBL11042794 | 0.77 | CCNE1 (0.41) | CCNE1CDK2GSK3BALDH1A1KMT2A | |
| SCHEMBL31212621 | 0.76 | MGLL (0.39) | CCNE1CDK2GSK3BMGLLALDH1A1 | |
| SCHEMBL874424 | 0.76 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3181566-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| WO-2013142269-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142269-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| EP-2619208-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012040230-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040230-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | CCNE1 4461/4885CDK2 1418/4885GSK3B 1917/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | CCNE1 4676/4885CDK2 2123/4885GSK3B 1941/4885 |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | CCNE1 4461/4885CDK2 1418/4885GSK3B 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.